ArticleClinical oral investigations2026
Impact of smoking on gremlin-1, syndecan-4, and IL-1β responses to non-surgical periodontal therapy in stage 3 periodontitis: a comparative study with periodontally healthy controls.
Article in Clinical oral investigations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to compare the periodontal status of periodontally healthy individuals with those of smokers and non-smokers with stage 3 periodontitis before and after treatment, as well as to investigate the levels of Gremlin-1, Syndecan-4, and IL-1β in GCF samples. Another objective of the study was to evaluate the relationship between these biomarkers and periodontitis and to assess the effects of smoking on their levels. MATERIALS AND
methodsA total of 45 volunteers, 15 smokers (Group SP) and 15 non-smokers (Group NP) diagnosed with stage 3 periodontitis between the ages of 18 and 60, and 15 healthy individuals (Group H) were included in the study.
resultsAll clinical parameters of the SP and NP groups were found to be significantly higher than those of the H group before NSPT (p<0.001), and a significant reduction was observed in all clinical parameters after phase I treatment (p<0.001). Following NSPT, significant improvement was observed in all periodontal parameters in both periodontitis groups (p<0.001). Gremlin-1 levels in the SP and NP groups were statistically significantly lower after treatment compared to pre-treatment levels (p<0.05). While there was no statistically significant difference in IL-1β levels before and after treatment in the SP group (p>0.05), a statistically significant reduction was observed in the NP group after treatment (p<0.05). Similarly, no statistically significant difference was found in Syndecan-4 levels before and after treatment in the SP group (p>0.05), whereas the post-treatment measurements of the NP group were statistically significantly lower (p<0.05).
conclusionsAfter NSPT, Gremlin-1 levels in GCF decreased in both groups, whereas significant reductions in Syndecan-4 and IL-1β levels were observed only in non-smokers. These findings suggest that the regulatory effect of smoking on biomarkers may negatively influence the periodontal treatment response. CLINICAL RELEVANCE: Smoking is a major risk factor for periodontitis and may impair healing following nonsurgical periodontal therapy. While similar clinical improvements were observed, reductions in IL-1β and Syndecan-4 occurred only in non-smokers, whereas Gremlin-1 decreased in both groups. These findings suggest that smoking may influence molecular healing responses, and biomarker monitoring may support personalized periodontal management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.